Neuroendocrine carcinoma of the common bile duct associated with congenital bile duct dilatation: a case report.
Adjuvant chemotherapy
Case report
Cholangiocarcinoma
Congenital bile duct dilatation
Large cell neuroendocrine carcinoma
Neuroendocrine carcinoma
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
12 Jun 2021
12 Jun 2021
Historique:
received:
14
01
2021
accepted:
20
04
2021
entrez:
13
6
2021
pubmed:
14
6
2021
medline:
16
6
2021
Statut:
epublish
Résumé
Cholangiocarcinoma is frequently observed in patients with congenital bile duct dilatation (CBDD). Most cholangiocarcinomas are adenocarcinomas. Other types, especially neuroendocrine carcinomas (NECs), are rare. To the best of our knowledge, this is the third reported case of an NEC of the common bile duct associated with CBDD and the first to receive adjuvant chemotherapy for advanced disease. A 29-year-old woman presented with upper abdominal pain. Preoperative imaging indicated marked dilatation of the common bile duct and a tumor in the middle portion of the common bile duct. She was suspected of having distal cholangiocarcinoma associated with CBDD and underwent pylorus-preserving pancreaticoduodenectomy. Pathological and immunohistological findings led to a final diagnosis of large-cell NEC (pT3aN1M0 pStageIIB). The postoperative course was uneventful, and she was administered cisplatin and irinotecan every 4 weeks (four cycles) as adjuvant chemotherapy. She has remained recurrence-free for 16 months. NEC might be a differential diagnosis in cases of cholangial tumor associated with congenital bile duct dilatation. This presentation is rare and valuable, and to establish better treatment for NEC, further reports are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Cholangiocarcinoma is frequently observed in patients with congenital bile duct dilatation (CBDD). Most cholangiocarcinomas are adenocarcinomas. Other types, especially neuroendocrine carcinomas (NECs), are rare. To the best of our knowledge, this is the third reported case of an NEC of the common bile duct associated with CBDD and the first to receive adjuvant chemotherapy for advanced disease.
CASE PRESENTATION
METHODS
A 29-year-old woman presented with upper abdominal pain. Preoperative imaging indicated marked dilatation of the common bile duct and a tumor in the middle portion of the common bile duct. She was suspected of having distal cholangiocarcinoma associated with CBDD and underwent pylorus-preserving pancreaticoduodenectomy. Pathological and immunohistological findings led to a final diagnosis of large-cell NEC (pT3aN1M0 pStageIIB). The postoperative course was uneventful, and she was administered cisplatin and irinotecan every 4 weeks (four cycles) as adjuvant chemotherapy. She has remained recurrence-free for 16 months.
CONCLUSIONS
CONCLUSIONS
NEC might be a differential diagnosis in cases of cholangial tumor associated with congenital bile duct dilatation. This presentation is rare and valuable, and to establish better treatment for NEC, further reports are necessary.
Identifiants
pubmed: 34118881
doi: 10.1186/s12876-021-01777-7
pii: 10.1186/s12876-021-01777-7
pmc: PMC8196520
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257Références
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
J Hepatobiliary Pancreat Surg. 1999;6(3):207-12
pubmed: 10526053
Medicine (Baltimore). 2018 Jul;97(29):e11487
pubmed: 30024526
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Endocr Pathol. 2020 Mar;31(1):84-93
pubmed: 31981075
Br J Cancer. 2020 Apr;122(9):1309-1314
pubmed: 32152503
Langenbecks Arch Surg. 2009 Jan;394(1):159-69
pubmed: 18500533
J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):754-60
pubmed: 24895231
World J Gastroenterol. 2016 Aug 14;22(30):6960-4
pubmed: 27570432
Cancer. 1979 Sep;44(3):1134-41
pubmed: 383269
Dig Surg. 2010;27(2):100-4
pubmed: 20551651
Clin Cancer Res. 2020 May 1;26(9):2124-2130
pubmed: 31980466
Nihon Shokakibyo Gakkai Zasshi. 2016;113(12):1991-1997
pubmed: 27916765
Cytopathology. 2016 Apr;27(2):97-102
pubmed: 25689921
Clin Cancer Res. 2020 Sep 1;26(17):4454-4459
pubmed: 32532787
J Pediatr Surg. 2009 Jun;44(6):E23-5
pubmed: 19524713
Ann Diagn Pathol. 2009 Dec;13(6):378-83
pubmed: 19917473
J Gastroenterol. 2015 Mar;50(3):273-9
pubmed: 25404143
World J Gastrointest Oncol. 2010 Mar 15;2(3):130-5
pubmed: 21160820
Cancer. 2020 Jul 1;126(13):3021-3030
pubmed: 32320048
Int Surg. 2012 Oct-Dec;97(4):315-20
pubmed: 23294072
Neuroendocrinology. 2012;96(4):324-32
pubmed: 22572060